June 27, 2015

Today was my youngest child's birthday! It amazes me how time has flown and the little tiny peanut she was is no longer. Though I miss my tiny little peanut, it is so exciting to see her grow and learn every day. She is becoming quite the character and is the sweetest cuddle bug I know.

The day of her birthday we were supposed to have a baseball tournament that ended up getting rained out so it was a great opportunity for us to spend the day with her. Even though she was disappointed that she didn't get to hang out with her baseball family we made sure she had a great day which in the end included some of our baseball family.

So proud to have the privilege of being her mother.

Love,
Jessica Cassidy
Mrs. Michigan International 2015

BEAT AML

The Leukemia & Lymphoma Society (LLS) has more good news to share about acute myeloid leukemia (AML)! Celator Pharmaceuticals, an important biotechnology partner in LLS’s Therapy Acceleration Program, released data this week regarding its study of an experimental therapy – a special formulation of two standard chemotherapy drugs to treat elderly patients with high-risk AML. The new therapy performed better than the standard course of treatment currently used. With a patient response rate of more than 47%, this news is very encouraging as it represents a positive advance for patients with few options for effective treatment. We’ve been telling you that AML is an aggressive blood cancer with a survival rate of just more than 25% across all cases and how treatment hasn’t changed for more than 30 years. We believe this is about to change. We set a goal of $300,000 by June 30 to support our Beat AML collaboration with Oregon Health & Science University, and, thanks to supporters like you, we reached it with a few days to spare. But like LLS researchers, we won’t stop there. Please join us in surpassing our goal, because it’s time for a cure. Thank you, Michael C. Copley National Chairman LLS's Beat AML Campaign

If you need help or to learn more about specific blood cancers: www.lls.org/diseaseinformation/ National Office 1311 Mamaroneck Avenue  |  White Plains, NY 10605  |  888.557.7177  |  www.LLS.org © 2015 The Leukemia & Lymphoma Society  |  All Rights Reserved This email was sent to: jcassidy@seniorplanningadvisors.com If you no longer wish to receive these emails, please reply to this message with "Unsubscribe" in the subject line or click on the following link: Unsubscribe To ensure future delivery of emails, please add newsletter@email.lls.org to your safe sender list or address book. About LLS: www.LLS.org | Facebook | Twitter | YouTube | Google+ | Disclaimer | Public Disclosure

LLS Research Grant

THE DAY HAS COME!!!
 
It is with the utmost excitement to be able to announce that with great dedication comes great reward!

With our continued work to advocate and raise funds for LLS we are finally able to name a research grant in honor of my late father-in-law which will specifically target immunotherapy research.
 
After careful consideration and understanding the side effects of chemotherapy and radiation we chose Dr. Carl June for his advancement in the immunotherapy realm of research. We are of the belief that immunotherapy treatments are less invasive and will be the future of successful treatments for blood cancer and other cancers.
 
We are looking forward to the journey of what may resolve from this research grant and are so joyful to be a small part of his work!
 
For those of you who are interested in the phase of research we have chosen, here's a little information on Dr. Carl June out of the University of Pennsylvania!
Love,
Jessica Cassidy
Mrs. Michigan International 2015
 

CARL JUNE, MD
UNIVERSITY OF PENNSYLVANIA

 

The goal of this collaborative research team is to develop chimeric antigen receptor (CAR) modified T cells to treat leukemia and lymphoma. The investigation consists of four synergistic projects.

 

Dr. June and his LLS-funded team have made significant advances, including immunotherapies that employ a patients' own normal T cells genetically modified  to display a CAR molecule that targets CD19, a protein found on many lymphoid cancers. CD19 CAR-T cells have achieved remissions for adults with chronic lymphocytic leukemia (CLL) and children with acute lymphoid leukemia (ALL) who had not achieved stable remissions with multiple standard therapies.

 

The team is now working to discover antigens that can be recognized in CD19-negative ALLs and other blood cancers, including lymphomas and acute myeloid leukemia's. In addition, they are further improving CAR engineering and delivery technologies, testing new CAR-T cells in appropriate animal models, and beginning clinical testing of new strategies including ones that use engineered T cells from donors.

Dr. Louis DeGennaro, PhD

Its not every day that your family receives a thank you note in the mail from the President and CEO of the Leukemia and Lymphoma Society! Thank you Dr. DeGennaro for your support and recognition! We are looking forward to Dr. June's continued successes in finding better cures for blood cancer patients!
Love,
Jessica Cassidy
Mrs. International 2015

LEUKEMIA AND LYMPHOMA SOCIETY LEGACY CIRCLE

June 11th, 2015

Today was our LTN Corporate Kick-off at the Gandy Dancer! What a great way to welcome new faces and provide information about LLS and how to get involved in our campaign to support blood cancer research!

I was asked to be the mission speaker by sharing my journey with the Leukemia and Lymphoma Society and why I continue to advocate and raise funds for their mission. I was so honored to be able to share my story and truly convey that LLS is family and because of their dedication to blood cancer research lives will be saved.

 

                                                     What an honor!

                                                       Love,

                                                      Jessica Cassidy

                                                      Mrs. Michigan International 2015

June 10th, 2015

It's always a pleasure to get together with the Executive Committee for the Light the Night Campaign for LLS. We have a great group working to make the Ann Arbor event a memorable one. We are so excited to be able to host the LTN walk in A2 this year where much of the LLS funded blood cancer research takes place. This year we have decided on the University of Michigan North Campus Research Campus (NCRC). Once the festivities to kick off the event we will be walking around the campus where our donor dollars are at work!

NCRC is such a monumental place for our walk to take place in and around as there are a total of 13 LLS funded researchers at the University of Michigan all working to find better cures for blood cancer patients. This is the largest number of researchers concentrated in one area focused on blood cancer research across the country.

After discussing all of the logistics information, Adam Chiasson, Site Leader at BD Biosciences gave us a tour of the facilities where they construct the cytometers which are specifically used for blood cancer and then asked us to be celebrity judges for the derby car esthetics for their annual internal Derby Car Race! Thanks Adam!

So excited to be a part of an amazing organization and a great team!

Love,
Jessica Cassidy
Mrs. Michigan International 2015